Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study

AIMS: An anti-angiogenic cleaved prolactin fragment is considered causal for peripartum cardiomyopathy (PPCM). Experimental and first clinical observations suggested beneficial effects of the prolactin release inhibitor bromocriptine in PPCM. METHODS AND RESULTS: In this multicentre trial, 63 PPCM p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hilfiker-Kleiner, Denise, Haghikia, Arash, Berliner, Dominik, Vogel-Claussen, Jens, Schwab, Johannes, Franke, Annegret, Schwarzkopf, Marziel, Ehlermann, Philipp, Pfister, Roman, Michels, Guido, Westenfeld, Ralf, Stangl, Verena, Kindermann, Ingrid, Kühl, Uwe, Angermann, Christiane E., Schlitt, Axel, Fischer, Dieter, Podewski, Edith, Böhm, Michael, Sliwa, Karen, Bauersachs, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Fast Track Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837241/
https://www.ncbi.nlm.nih.gov/pubmed/28934837
http://dx.doi.org/10.1093/eurheartj/ehx355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837241/
https://www.ncbi.nlm.nih.gov/pubmed/28934837
http://dx.doi.org/10.1093/eurheartj/ehx355

Ejemplares similares